ArticleTherapeutic advances in medical oncology2020
Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study).
Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Tumor Cell Proportion Assessment in Advanced Non-Squamous Non-Small Cell Lung Cancer Tissue Samples in Real-World Settings in Japan: The ASTRAL Study.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.JAMA network open · 2023Article
- Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.Cancer medicine · 2023Observational
- Article
- Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study.BMC pulmonary medicine · 2023Article
- Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.Cancer science · 2023Observational
- Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.Thoracic cancer · 2022Article
- Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario.Journal of market access & health policy · 2022Article
- Case report: NovelFrontiers in oncology · 2022Article
- Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan.JTO clinical and research reports · 2021Article
- Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing.Diagnostics (Basel, Switzerland) · 2021Article
- Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice.Thoracic cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMolecular diagnostic testing is necessary to guide optimal first-line treatment. The number of patients who receive first-line treatment based on biomarker analysis in Japan is unknown. We aimed to determine the proportion of nonsquamous non-small cell lung cancer (NSCLC) patients for whom first-line treatment was selected based on biomarker testing.
methodsThis retrospective, multicenter, observational study registered patients aged ⩾20 years with locally advanced or metastatic nonsquamous NSCLC who started first-line treatment between August and December 2017 in Japan. Data were collected from medical records between January and May 2018. The primary endpoint was the proportion of patients with confirmed biomarker status for first-line treatment decision.
resultsAmong 202 patients enrolled from 11 centers, 161 (79.7%; 95% confidence interval, 74.2-85.2%) had confirmed biomarker status. The testing rate was highest for epidermal growth factor receptor (
conclusionsThe proportion of nonsquamous NSCLC patients with confirmed biomarker status for first-line treatment was considered insufficient and in need of improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.